Liver Fibrosis Scores and Clinical Outcomes in Patients With COVID-19

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2022 Apr 25

PMID 35463006

Authors

Jing Zhang

Fuwei Liu

Tiangang Song

Zhangwang Li

Panpan Xia

Xiaoyi Tang

Minxuan Xu

Yunfeng Shen

Jianyong Ma

Xiao Liu

Peng Yu

Affiliations

Soon will be listed here.

Abstract

Background And Aims: We investigated the association between liver fibrosis scores and clinical outcomes in patients with COVID-19.

Methods: We performed a analysis among patients with COVID-19 from the trial study Outcomes Related to COVID-19 treated with Hydroxychloroquine among Inpatients with symptomatic Disease (ORCHID) trial. The relationship between aspartate aminotransferase (AST) to platelet ratio index (APRI), non-alcoholic fatty liver disease fibrosis score (NFS), Fibrosis-4 index (FIB-4), and discharge and death during the 28-days of hospitalization was investigated.

Results: During the 28 days after randomization, 237 (80.6%) patients were discharged while 31 (10.5%) died among the 294 patients with COVID-19. The prevalence for advanced fibrosis was estimated to be 34, 21.8, and 37.8% for FIB-4 (>2.67), APRI (>1), and NFS (>0.676), respectively. In multivariate analysis, FIB-4 >2.67 [28-days discharge: hazard ratio (HR): 0.62; 95% CI: 0.46-0.84; 28-days mortality: HR: 5.13; 95% CI: 2.18-12.07], APRI >1 (28-days discharge: HR: 0.62; 95% CI: 0.44-0.87; 28-days mortality: HR: 2.85, 95% CI: 1.35-6.03), and NFS >0.676 (28-days discharge: HR: 0.5; 95% CI: 0.35-0.69; 28-days mortality: HR: 4.17; 95% CI: 1.62-10.72) was found to significantly reduce the discharge rate and increase the risk of death. Additionally, FIB-4, APRI, and NFS were found to have good predictive ability and calibration performance for 28-day death (C-index: 0.74 for FIB-4, 0.657 for APRI, and 0.745 for NFS) and discharge (C-index: 0.649 for FIB-4, 0.605 for APRI, and 0.685 for NFS).

Conclusion: In hospitalized patients with COVID-19, FIB-4, APRI, and NFS may be good predictors for death and discharge within 28 days. The link between liver fibrosis and the natural history of COVID-19 should be further investigated.

Citing Articles

Predicting Severe COVID-19 Outcomes in the Elderly: The Role of Systemic Immune Inflammation, Liver Function Tests, and Neutrophil-to-Lymphocyte Ratio.

Bota A, Marc F, Adelina M, Nicolescu L, Tudora A, Cotoraci C Healthcare (Basel). 2024; 12(23).

PMID: 39685051 PMC: 11641812. DOI: 10.3390/healthcare12232429.

Association between Liver Damage and Disease Progression Markers with Mortality Risk and Mechanical Ventilation in Hospitalized COVID-19 Patients: A Nationwide Retrospective SARSTer Study.

Zmudka K, Jaroszewicz J, Zarebska-Michaluk D, Rogalska M, Czupryna P, Rorat M Viruses. 2024; 16(10).

PMID: 39459864 PMC: 11512261. DOI: 10.3390/v16101530.

Comparison of liver fibrosis scores and fatty liver on computed tomography as risk factors for severity of COVID-19.

Kamiya Y, Shinoda M, Ishii N, Yamamoto S, Sekine T, Morikawa M JGH Open. 2024; 8(8):e70004.

PMID: 39130093 PMC: 11310555. DOI: 10.1002/jgh3.70004.

The Role of APRI, FIB-4, and SAD-60 Scores as Predictors of Mortality in COVID-19 Patients.

Copur B, Surme S, Tuncer G, Bayramlar O Infect Dis Clin Microbiol. 2024; 5(2):144-152.

PMID: 38633008 PMC: 10985813. DOI: 10.36519/idcm.2023.233.

COVID-19 and hepatic injury: cellular and molecular mechanisms in diverse liver cells.

Ali F, Abd El-Aziz M, Ali M, Ghogar O, Bakr A World J Gastroenterol. 2023; 29(3):425-449.

PMID: 36688024 PMC: 9850933. DOI: 10.3748/wjg.v29.i3.425.

References

Self W, Semler M, Leither L, Casey J, Angus D, Brower R . Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2020; 324(21):2165-2176. PMC: 7653542. DOI: 10.1001/jama.2020.22240. View

Li Y, Regan J, Fajnzylber J, Coxen K, Corry H, Wong C . Liver Fibrosis Index FIB-4 Is Associated With Mortality in COVID-19. Hepatol Commun. 2021; 5(3):434-445. PMC: 7753559. DOI: 10.1002/hep4.1650. View

Kim D, Adeniji N, Latt N, Kumar S, Bloom P, Aby E . Predictors of Outcomes of COVID-19 in Patients With Chronic Liver Disease: US Multi-center Study. Clin Gastroenterol Hepatol. 2020; 19(7):1469-1479.e19. PMC: 7497795. DOI: 10.1016/j.cgh.2020.09.027. View

Calapod O, Marin A, Onisai M, Tribus L, Pop C, Fierbinteanu-Braticevici C . The Impact of Increased Fib-4 Score in Patients with Type II Diabetes Mellitus on Covid-19 Disease Prognosis. Medicina (Kaunas). 2021; 57(5). PMC: 8147130. DOI: 10.3390/medicina57050434. View

Sterling R, Oakes T, Gal T, Stevens M, DeWit M, Sanyal A . The Fibrosis-4 Index Is Associated With Need for Mechanical Ventilation and 30-Day Mortality in Patients Admitted With Coronavirus Disease 2019. J Infect Dis. 2020; 222(11):1794-1797. PMC: 7499595. DOI: 10.1093/infdis/jiaa550. View

Qin C, Wei Y, Lyu X, Zhao B, Feng Y, Li T . High aspartate aminotransferase to alanine aminotransferase ratio on admission as risk factor for poor prognosis in COVID-19 patients. Sci Rep. 2020; 10(1):16496. PMC: 7536227. DOI: 10.1038/s41598-020-73575-2. View

Tian D, Ye Q . Hepatic complications of COVID-19 and its treatment. J Med Virol. 2020; 92(10):1818-1824. PMC: 7280725. DOI: 10.1002/jmv.26036. View

Xiang F, Sun J, Chen P, Han P, Zheng H, Cai S . Early Elevation of Fibrosis-4 Liver Fibrosis Score Is Associated With Adverse Outcomes Among Patients With Coronavirus Disease 2019. Clin Infect Dis. 2021; 73(3):e594-e601. PMC: 7717224. DOI: 10.1093/cid/ciaa1710. View

Goel H, Harmouch F, Garg K, Saraiya P, Daly T, Kumar A . The liver in COVID-19: prevalence, patterns, predictors, and impact on outcomes of liver test abnormalities. Eur J Gastroenterol Hepatol. 2020; 33(1S Suppl 1):e274-e281. PMC: 8734568. DOI: 10.1097/MEG.0000000000002021. View

10.

Vilar-Gomez E, Chalasani N . Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. J Hepatol. 2017; 68(2):305-315. DOI: 10.1016/j.jhep.2017.11.013. View

11.

Ji D, Qin E, Xu J, Zhang D, Cheng G, Wang Y . Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. J Hepatol. 2020; 73(2):451-453. PMC: 7141624. DOI: 10.1016/j.jhep.2020.03.044. View

12.

Cai X, Sun L, Liu X, Zhu H, Zhang Y, Zheng S . Non-alcoholic fatty liver disease is associated with increased risk of chronic kidney disease. Ther Adv Chronic Dis. 2021; 12:20406223211024361. PMC: 8237225. DOI: 10.1177/20406223211024361. View

13.

Del Zompo F, De Siena M, Ianiro G, Gasbarrini A, Pompili M, Ponziani F . Prevalence of liver injury and correlation with clinical outcomes in patients with COVID-19: systematic review with meta-analysis. Eur Rev Med Pharmacol Sci. 2020; 24(24):13072-13088. DOI: 10.26355/eurrev_202012_24215. View

14.

Parohan M, Yaghoubi S, Seraji A . Liver injury is associated with severe coronavirus disease 2019 (COVID-19) infection: A systematic review and meta-analysis of retrospective studies. Hepatol Res. 2020; 50(8):924-935. PMC: 7273097. DOI: 10.1111/hepr.13510. View

15.

von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007; 147(8):573-7. DOI: 10.7326/0003-4819-147-8-200710160-00010. View

16.

Schonmann Y, Yeshua H, Bentov I, Zelber-Sagi S . Liver fibrosis marker is an independent predictor of cardiovascular morbidity and mortality in the general population. Dig Liver Dis. 2020; 53(1):79-85. DOI: 10.1016/j.dld.2020.10.014. View

17.

Chun H, Lee J, Lee H, Kim B, Park J, Kim D . Association between the severity of liver fibrosis and cardiovascular outcomes in patients with type 2 diabetes. J Gastroenterol Hepatol. 2020; 36(6):1703-1713. DOI: 10.1111/jgh.15387. View

18.

Casey J, Johnson N, Semler M, Collins S, Aggarwal N, Brower R . Rationale and Design of ORCHID: A Randomized Placebo-controlled Clinical Trial of Hydroxychloroquine for Adults Hospitalized with COVID-19. Ann Am Thorac Soc. 2020; 17(9):1144-1153. PMC: 7462324. DOI: 10.1513/AnnalsATS.202005-478SD. View

19.

Elfeki M, Robles J, Akhtar Z, Ullah F, Ganapathiraju I, Tran C . Impact of Fibrosis-4 Index Prior to COVID-19 on Outcomes in Patients at Risk of Non-alcoholic Fatty Liver Disease. Dig Dis Sci. 2021; 67(7):3333-3339. PMC: 8233600. DOI: 10.1007/s10620-021-07120-0. View

20.

Behzad S, Aghaghazvini L, Radmard A, Gholamrezanezhad A . Extrapulmonary manifestations of COVID-19: Radiologic and clinical overview. Clin Imaging. 2020; 66:35-41. PMC: 7233216. DOI: 10.1016/j.clinimag.2020.05.013. View